Chiasma

OverviewSuggest Edit

Chiasma applies its proprietary technology to approved drugs, which not only enables their being switched from injectable to oral, but importantly can result in new indications and/or enhanced absorption. The Company's Transient Permeability Enhancer technology promotes the delivery of drugs to the GI wall and from there to the liver. It is applicable to macromolecules that to-date can be administered only by injection. TPE can be utilized also with small molecules that are already orally available but are poorly absorbed.
TypePublic
Founded2001
HQNeedham, MA, USMap
Websitechiasmapharma.com
Employee Ratings4.5More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Mar 2020)48(+167%)
Revenue (FY, 2020)$1.1 M
Share Price (Mar 2021)$3(+2%)
Cybersecurity ratingCMore

Key People/Management at Chiasma

Roni Mamluk

Roni Mamluk

CEO
Dana Gelbaum

Dana Gelbaum

VP of BD and Supply Chain
Shoshie Katz

Shoshie Katz

VP of Quality Assurance & Regulatory Affairs
Asi Haviv

Asi Haviv

VP of Clinical Development
Lillian Kuan

Lillian Kuan

Alumni Advisory Committee Board Member
Show more

Chiasma Office Locations

Chiasma has offices in Needham, Waltham and Ness Ziona
Needham, MA, US (HQ)
140 Kendrick St Building C
Waltham, MA, US
460 Totten Pond Rd #530
Ness Ziona, IL
5 Golda Me'ir St
Show all (3)

Chiasma Financials and Metrics

Chiasma Revenue

Chiasma's revenue was reported to be $1.11 m in FY, 2020
USD

Revenue (FY, 2020)

1.1m

Gross profit (FY, 2020)

1.0m

Gross profit margin (FY, 2020), %

94.5%

Net income (FY, 2020)

(74.8m)

EBIT (FY, 2020)

(70.6m)

Market capitalization (30-Mar-2021)

173.5m

Closing stock price (30-Mar-2021)

3.0

Cash (31-Dec-2020)

15.5m

EV

158.7m
Chiasma's current market capitalization is $173.5 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

1.1m

Cost of goods sold

61.0k

Gross profit

1.0m

Gross profit Margin, %

94%
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

142.0k

Cost of goods sold

3.0k

Gross profit

139.0k

Gross profit Margin, %

98%
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

41.0m37.0m14.6m13.1m27.9m15.5m

Accounts Receivable

538.0k

Prepaid Expenses

1.8m2.2m3.9m6.4m

Inventories

2.3m2.1m11.0m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

63.3m140.9m39.1m30.5m28.5m19.0m18.4m12.1m15.2m13.8m11.2m10.1m20.6m19.7m42.6m52.2m72.8m

Accounts Receivable

179.0k

Prepaid Expenses

466.0k1.4m3.8m2.5m2.2m1.8m1.4m2.2m1.7m1.2m1.7m1.4m1.1m3.0m4.9m3.7m5.4m

Inventories

8.9m
show all
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(35.9m)(61.1m)(26.8m)(31.3m)(36.3m)(74.8m)

Depreciation and Amortization

201.0k433.0k152.0k88.0k55.0k172.0k

Inventories

(1.7m)674.0k(10.9m)

Accounts Payable

(161.0k)1.8m(1.6m)4.3m111.0k6.2m
Quarterly
USDQ2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(12.0m)(21.4m)(17.2m)(43.8m)(53.2m)(7.0m)(13.9m)(20.7m)(7.0m)(15.7m)(23.2m)(8.7m)(16.6m)(24.3m)(15.4m)(36.5m)(55.0m)

Depreciation and Amortization

98.6k146.2k59.0k153.0k373.0k40.0k79.0k119.0k23.0k46.0k69.0k16.0k29.0k42.0k26.0k73.0k122.0k

Inventories

(8.9m)

Accounts Payable

358.5k366.0k(457.0k)(670.0k)(613.0k)1.7m3.1m3.2m(751.0k)(1.2m)(1.9m)2.9m5.8m7.7m
show all
USDQ2, 2015

Financial Leverage

-0.8 x
Show all financial metrics

Chiasma Cybersecurity Score

Cybersecurity ratingPremium dataset

C

77/100

Learn more about our premium products
SecurityScorecard logo

Chiasma Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

Chiasma Online and Social Media Presence

Chiasma's Trends

Embed Graph

Chiasma News and Updates

March 10, 2021

Chiasma to Present New Data from Two Phase 3 Trials, CHIASMA OPTIMAL and MPOWERED™, at ENDO 2021

-- One oral presentation and five late-breaking posters accepted -- NEEDHAM, Mass., March 10, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), (“Chiasma” or the “Company”), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize or…
March 02, 2021

Chiasma to Participate in the H.C. Wainwright Global Life Sciences Conference

NEEDHAM, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company, today announced that management will present a company overview at the H.C. Wainwright Global Life Sciences Conference, which is being held Tuesday, March 9th - Wednesday,…
February 25, 2021

Chiasma to Report Fourth Quarter 2020 Results on March 4

Company to host conference call and webcast at 5:00 p.m. ET Company to host conference call and webcast at 5:00 p.m. ET
January 19, 2021

Chiasma Announces Hiring of John Doyle as Chief Financial Officer

Appointment provides extensive commercial-stage public company financial leadership experience Appointment provides extensive commercial-stage public company financial leadership experience
November 23, 2020

Chiasma to Participate in Two Investor Conferences in December

NEEDHAM, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injectio…
November 20, 2020

Chiasma to Host an Expert Panel on Acromegaly and the MPOWERED® Phase 3 Trial Results

NEEDHAM, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ: CHMA), a commercial-stage biopharmaceutical company utilizing its delivery platform technology to develop and commercialize oral therapies to improve the lives of patients with rare diseases on burdensome and painful injectio…
Show more

Chiasma Blogs

March 20, 2021

Chiasma Presents New Positive Data for MYCAPSSA from Phase 3 Trial MPOWERED™ for the Maintenance Treatment of Acromegaly at ENDO 2021

--Data supports MYCAPSSA ® as non-inferior to long-acting   injectable somatostatin receptor ligands (iSRLs)-- --Data demonstrated patients taking MYCAPSSA had significant improvement in acromegaly related symptoms and patient reported outcomes after s... The post Chiasma Presents New Positive Data …
March 04, 2021

Chiasma Reports Fourth Quarter and Full-Year 2020 Financial Results and Provides Corporate Update

Phased launch of MYCAPSSA ® progressing with 2020 net product revenue of $1.1 million Achieved payor coverage of MYCAPSSA for over 150 million lives Company to host conference call today, March 4, 2021 at 5:00pm ET NEEDHAM, Mass. , March 04, 2021 (GLOB... The post Chiasma Reports Fourth Quarter and …
January 06, 2021

Chiasma Provides Corporate Update and Previews Expected 2021 Milestones

MYCAPSSA ® launch in US continuing to gain traction with physicians, patients, and payers MYCAPSSA ®   EMA submission for EU marketing approval on track for mid-2021 following positive results of MPOWERED Phase 3 clinical trial NEEDHAM, Mass. , Jan. 06... The post Chiasma Provides Corporate Update a…
March 16, 2020

Chiasma Reports Fourth Quarter and Full Year 2019 Financial Results

Chiasma Reports Fourth Quarter and Full Year 2019 Financial Results Content Import Mon, 03/16/2020 - 16:05 Chiasma Reports Fourth Quarter and Full Year 2019 Financial Results March 16, 2020 at 4:05 PM EDT This release is a backfill from a News Wire …
March 09, 2020

Chiasma To Report Fourth Quarter and Full Year 2019 Financial Results On March 16, 2020

Chiasma To Report Fourth Quarter and Full Year 2019 Financial Results On March 16, 2020 Content Import Mon, 03/09/2020 - 16:05 Chiasma To Report Fourth Quarter and Full Year 2019 Financial Results On March 16, 2020 March 9, 2020 at 4:05 PM EDT This release is …
January 13, 2020

Chiasma Announces FDA Acceptance of MYCAPSSA® New Drug Application Resubmission

Chiasma Announces FDA Acceptance of MYCAPSSA® New Drug Application Resubmission Content Import Mon, 01/13/2020 - 07:01 Chiasma Announces FDA Acceptance of MYCAPSSA® New Drug Application Resubmission January 13, 2020 at 7:00 AM EST This release is a backfill fr…
Show more

 Chiasma Frequently Asked Questions

  • When was Chiasma founded?

    Chiasma was founded in 2001.

  • Who are Chiasma key executives?

    Chiasma's key executives are Roni Mamluk, Dana Gelbaum and Shoshie Katz.

  • How many employees does Chiasma have?

    Chiasma has 48 employees.

  • What is Chiasma revenue?

    Latest Chiasma annual revenue is $1.1 m.

  • What is Chiasma revenue per employee?

    Latest Chiasma revenue per employee is $23 k.

  • Who are Chiasma competitors?

    Competitors of Chiasma include Laboratorios Bago, Merz North America and Libbs Farmaceutica.

  • Where is Chiasma headquarters?

    Chiasma headquarters is located at 140 Kendrick St Building C, Needham.

  • Where are Chiasma offices?

    Chiasma has offices in Needham, Waltham and Ness Ziona.

  • How many offices does Chiasma have?

    Chiasma has 3 offices.